Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Immunoglobulins A, G, and M to cytomegalovirus during recurrent infection in recipients of allogenic bone marrow transplantation

Article Abstract:

A major and sometimes fatal complication of bone marrow transplantation is infection with cytomegalovirus (CMV), which is a form of herpes virus. In recurrent infection with CMV, antibodies - specifically immunoglobulins - develop and they are of three basic types: IgA, IgM, and IgG. In order to evaluate the incidence of production of these three immunoglobulins in response to recurrent CMV infection in patients who have undergone bone marrow transplant (BMT), 21 BMT patients who were CMV seropositive (i.e. had antibodies to the virus) but had not previously had CMV were studied. Seventeen patients were infected with CMV, of whom 16 secreted CMV virus in their urine. Fifteen had detectible levels of IgA, 13 had levels of IgM, and the levels of IgG quadrupled in 11 cases. The patients began to excrete virus in their urine an average of 69 days after the transplant, and while the elevated levels of IgA and IgM receded after about 14 and 30 days, respectively, the high levels of IgG tended to persist. It was also found that in the 12 patients who actually developed CMV disease, levels of IgA and IgM increased before the appearance of elevated IgG levels. The results suggest that IgA and IgM levels may be diagnostically relevant for BMT patients who have a history of recurrent CMV infection. (Consumer Summary produced by Reliance Medical Information, Inc.)

Author: Slavin, Shimon, Engelhard, Dan, Weinberg, Miriam, Or, Reuven, Shaked, Oshra, Naparstek, Elisabeth, Haikin, Hava, Sarov, Israel
Publisher: University of Chicago Press
Publication Name: Journal of Infectious Diseases
Subject: Health
ISSN: 0022-1899
Year: 1991
Diagnosis, Physiological aspects, Cytomegalovirus infections, Bone marrow, Bone marrow transplantation, Immunoglobulins

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Hoarseness can mean TB in kidney transplant recipients

Article Abstract:

The use of immunosuppressive drugs among renal transplant recipients have increased the incidence of opportunistic infections such as laryngeal tuberculosis in such patients. Thus, clinicians must consider laryngeal tuberculosis as a differential diagnosis for renal transplant recipients complaining of hoarseness. Two renal transplant recipients who were found to be positive for the acid-fast bacilli have responded well to tuberculosis drug therapy.

Author: Boyles, Salynn
Publisher: NewsRX
Publication Name: World Disease Weekly Plus
Subject: Health
ISSN:
Year: 1998
Diseases, Organ transplant recipients, Kidneys, Kidney transplantation, Immunosuppressive agents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA



Subjects list: Complications and side effects, Transplantation of organs, tissues, etc., Organ transplantation, Tissue transplantation, Transplantation
Similar abstracts:
  • Abstracts: Mechanism of disease induction by HIV. HIV infection in autologous and allogeneic bone marrow transplant patients: a retrospective analysis of the Marseille bone marrow transplant population
  • Abstracts: Ethics and economic realities: goals and strategies for care toward the end of life. Societal effects and other factors affecting health care for the elderly: report of the Council on Scientific Affairs
  • Abstracts: Dental implants used for periodontal patients. Regenerating the periodontium in advanced periodontal disease. Periodontal regeneration updated
  • Abstracts: The efficacy and clinical impact of brain imaging in neurologically symptomatic AIDS patients: a prospective CT/MRI study
  • Abstracts: Nazi science - The Dachau hypothermia experiments. Practical experiences in obtaining informed consent for a vaccine trial in rural Africa
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.